Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $30.33, but opened at $31.39. Twist Bioscience shares last traded at $31.40, with a volume of 340,104 shares trading hands.
Wall Street Analysts Forecast Growth
A number of brokerages have commented on TWST. Robert W. Baird lowered their target price on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. The Goldman Sachs Group reduced their price target on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Guggenheim reaffirmed a "buy" rating and issued a $50.00 price target on shares of Twist Bioscience in a research report on Tuesday, May 6th. JPMorgan Chase & Co. reduced their price target on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Finally, Barclays cut their price objective on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $50.40.
Check Out Our Latest Analysis on Twist Bioscience
Twist Bioscience Stock Performance
The firm has a fifty day simple moving average of $34.23 and a 200 day simple moving average of $41.89. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The stock has a market cap of $2.00 billion, a price-to-earnings ratio of -9.87 and a beta of 2.38.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.10). The company had revenue of $92.79 million during the quarter, compared to the consensus estimate of $92.00 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. As a group, sell-side analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current year.
Insider Buying and Selling at Twist Bioscience
In related news, CEO Emily M. Leproust sold 1,726 shares of the stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $41.68, for a total transaction of $71,939.68. Following the sale, the chief executive officer now directly owns 660,966 shares in the company, valued at $27,549,062.88. This represents a 0.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Paula Green sold 1,101 shares of the stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $37.65, for a total value of $41,452.65. Following the sale, the senior vice president now owns 129,380 shares in the company, valued at approximately $4,871,157. This trade represents a 0.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 23,012 shares of company stock valued at $817,752. 3.01% of the stock is currently owned by company insiders.
Institutional Trading of Twist Bioscience
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hodges Capital Management Inc. acquired a new stake in Twist Bioscience in the first quarter worth about $344,000. Rhumbline Advisers increased its position in Twist Bioscience by 5.0% in the first quarter. Rhumbline Advisers now owns 95,964 shares of the company's stock worth $3,768,000 after purchasing an additional 4,571 shares during the period. Strs Ohio acquired a new stake in Twist Bioscience in the first quarter worth about $711,000. Intech Investment Management LLC increased its position in Twist Bioscience by 18.9% in the first quarter. Intech Investment Management LLC now owns 28,917 shares of the company's stock worth $1,135,000 after purchasing an additional 4,591 shares during the period. Finally, Bayforest Capital Ltd increased its position in Twist Bioscience by 49.3% in the first quarter. Bayforest Capital Ltd now owns 4,860 shares of the company's stock worth $191,000 after purchasing an additional 1,604 shares during the period.
Twist Bioscience Company Profile
(
Get Free Report)
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Further Reading
Before you consider Twist Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.
While Twist Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.